Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab.

Tessa de VriesEloísa Rubio-BeltránAntoon van den BogaerdtRuben DammersAlexander H J DanserJosefin SnellmanJeanine BussiereAntoinette MaassenVanDenBrink

Published in: British journal of pharmacology (2024)

Gepants have additional effects on top of erenumab for CGRP-induced relaxation and could be effective in treating migraine attacks in patients already using erenumab as prophylaxis.

Keyphrases

end stage renal disease
endothelial cells
ejection fraction
newly diagnosed
chronic kidney disease
coronary artery disease
prognostic factors
high glucose
heart failure
diabetic rats
aortic stenosis
patient reported outcomes
induced pluripotent stem cells
single molecule
drug induced
blood flow